Presentation is loading. Please wait.

Presentation is loading. Please wait.

Radioiodine Treatment for Benign Thyroid Diseases Teofilo O.L. San Luis, Jr., MD, MPA Professor, Faculty of Medicine & Surgery, University of Santo Tomas.

Similar presentations


Presentation on theme: "Radioiodine Treatment for Benign Thyroid Diseases Teofilo O.L. San Luis, Jr., MD, MPA Professor, Faculty of Medicine & Surgery, University of Santo Tomas."— Presentation transcript:

1 Radioiodine Treatment for Benign Thyroid Diseases Teofilo O.L. San Luis, Jr., MD, MPA Professor, Faculty of Medicine & Surgery, University of Santo Tomas Chief, Section of Nuclear Medicine, UST Hospital, Manila, Philippines Dean, Asian School of Nuclear Medicine

2 I 131 Treatment Indicated for Hyperthyroidism (Graves Disease, Toxic Nodular Goiter), recurrent disease, those with contraindications to anti-thyroid drugs & surgery Not indicated for: Destruction-induced thyrotoxicosis Thyroiditis (acute, subacute, postpartum) Thyrotoxicosis factitia Hyperthyroxinemia Used in shrinking euthyroid goiters or nodules

3 What happens inside the Thyroid Follicular Cell? I 127

4 What happens inside the Thyroid Follicular Cell with I 131 ? I 131

5 I 131 Treatment I 131 emits beta rays (0.61 MeV); max range in tissue = 2.4mm Beta rays destruction of thyroid follicular cells decreased thyroid cell mass reduced thyroid hormones over a period of time Variability in how long a time is the effect of I 131 ? how much cell mass is destroyed? how much thyroid hormone can still be produced?

6 Factors affecting I 131 effectiveness: Dose itself Over-all gland size (or weight) Uptake into the thyroid Transit through the thyroid Status of iodine sufficiency (or deficiency) Radiation sensitivity

7 FACTOR # 1: DOSE ITSELF Dose Calculation Dose = Gland Weight x uCi/gm x 100 % Uptake (24 hrs) Considerable variation in any of the entries Fixed Dose vs. Calculated Dose vs. Empirical Dose 5 mCi; 10 mCi; 15 mCi 100 – 160 uCi / gm 5,000 – 15,000 rads or 50 – 150 Gy Physician subjective factors: clinical contingencies, urgency for treatment, severity of disease, etc.) Regulatory requirements: out-patient vs. in-patient

8 FACTOR # 2: GLAND SIZE (WEIGHT) Variability in gland size (weight estimation) Clinical palpation estimate (based on experience) Thyroid scan image estimate (eye-balling) Thyroid scan planimetry RL = Length x Width, e.g. 6 cm x 2.5 cm = 15.0 LL = Length x Width, e.g. 5.5 cm x 3 cm = cm 2 x constant (thickness) 1.44 = 45.3 cm 3 or 45 gms Ultrasound volume (machine-derived) RL = Length x Width x Depth x correction factor LL = Length x Width x Depth x correction factor 6 x 2.5 x 2.5 x 0.52 = x 3 x 2.5 x 0.52 = gms

9 FACTOR # 3: UPTAKE INTO THE ORGAN Hyperthyroid uptake ranges from 30 – 90% Distribution: uniform vs. non-uniform 24 hr RAIU & scan as appropriate indicators Therapy uptake decreased by iodine contaminants (food, drugs) FACTOR # 4: TRANSIT THROUGH THYROID (Biologic half-life) Hyperthyroid patients: very rapid thyroidal turnover of iodine = short biologic half-life Depleted thyroidal iodine pool (in 15% of pts) Rapid transit decreased thyroid radiation dose (but increased blood & marrow radioactivity) effectiveness?

10 FACTOR # 5: STATUS OF IODINE SUFFICIENCY (or DEFICIENCY) Intra-thyroidal iodine stores In iodine sufficient areas: 10 – 20 mg (mean: 15 mg) In iodine deficient areas: 2 – 5 mg (mean 3.5 mg) Competition of stable iodine vs. radioiodine Iodine-poor diet list, etc FACTOR # 6: RADIATION SENSITIVITY Difficult to measure Prior use of anti-thyroid drugs (PTU but not Methimazole) confers radio-resistance treatment failure vs use higher I 131 dose

11 I 131 Treatment Outcomes Effects on Thyroidal Physical Configuration Decrease in global size (for diffuse enlargement) Decrease in nodule number & dimensions (for nodular enlargement) Effects on Thyroidal Function Desired: Euthyroidism Inevitable: Hypothyroidism Unintended: Persistent hyperthyroidism Unfortunate / Inadvertent: Thyroid storm

12 I 131 Treatment Outcomes Clinical Thyroidal Outcomes Hypothyroidism: early (within 1 st year): 20%; 2 – 3% / annum; 50% within decade; +5% every 2 decades Clinical Non-Thyroidal Outcomes Risk for carcinogenesis: very little Other effects: hardly, if at all Non-Clinical Outcomes Safety & Efficiency Economic (Cost-Benefit)

13 I 131 Treatment: Summary I 131 has definitive role in the management of hyperthyroidism and other benign thyroid conditions, as appropriate Radiation effects influenced by several factors Effects on thyroidal physical configuration & function with projected variable outcomes I 131 therapy is safe, efficient, cost-beneficial

14 Thank you! Salamat Po! Muchas gracias! Merci beaucoup! Vielen Dank! Obrigado! Terimah kasih! Shoukran! Shukriya! Mamnun! Spaciba! Arigato gozaimas! Xie xie! Mesi! Kab Khun! Dank!


Download ppt "Radioiodine Treatment for Benign Thyroid Diseases Teofilo O.L. San Luis, Jr., MD, MPA Professor, Faculty of Medicine & Surgery, University of Santo Tomas."

Similar presentations


Ads by Google